HOPEWIND-ELECTRIC
28.5.2024 13:17:33 CEST | Business Wire | Press release
Hopewind (SHANGHAI STOCK EXCHANGE Code: 603063) has been officially nominated for the 2024 Smarter E award for its grid forming capable 385 kW utility-scale string inverter. Selected by jury for the Top 10 short list, makes Hopewind the only Chinese solar inverter manufacturer to reach the finals, highlighting the company's strong R&D capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240527117090/en/
Hopewind has been officially nominated for the 2024 Smarter E award (Photo: Business Wire)
“Our nomination for The Smarter E / Intersolar Award 2024 underlines our innovative nature that is core to our DNA,” said Wang Yao, Deputy General Manager of Hopewind.
Also in May, the Q2/2004 Global PV Market Outlook of Bloomberg New Energy Finance (BNEF) selected Hopewind to join its Tier 1 Photovoltaic Inverter Manufacturer list. “Ranking on BNEF’s prestigious Tier 1 list recognizes our financial and business strengths,” added Wang Yao, “and it confirms our strategy to delve deeper into the PV field, working on further innovations and breakthroughs to lead the development of global clean and renewable energy.”
As part of its innovation strategy, Hopewind officially joined the International Solar Energy Research Center Konstanz (ISC), one of world solar leading research institutes in April. Established in 2007, Hopewind was listed on the Shanghai Stock Exchange (Stock code: 603063) in 2017 as a leading innovator in the clean power generation industry, specializing in designing and producing renewable and electrical solutions, including wind power converters, PV inverters, battery storage systems (BESS), SVG, and industry drives with 150 GW+ shipments worldwide and GW production capacities.
Hopewind, participated in the Wingrid project, supported by the Horizon Europe 2020 and facilitated through the DNV Netherlands Laboratory. In 2023, Hopewind’s wind power converter received the world’s first grid forming certificate from DNV, with the 385kW inverter being selected as No.1 powerful solar string inverter by Solarbe Global since February, 2024.
Like in the Kubuqi Desert of Inner Mongolia, the seventh largest desert in China, an impressive transformation is taking place. Beneath over 10 kilometers of photovoltaic (PV) panels, herbs and pasture thrive, while chickens and goats roam and forage, bringing new life to the arid landscape.
The solar energy captured by these panels is converted into clean electricity by Hopewind 5,604 350kW inverters and fed into the power grid.
“This project showcases our corporate vision, which is to become a world-class provider of power conversion and control solutions, creating a more sustainable future for our world," Wang emphasized.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240527117090/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom